CTLA4 and melanoma: Ipilimumab is an antibody able to block the co-inhibitory receptor cytotoxic T-lymphocyte antigen-4 (CTLA-4) and the inhibition of CTLA-4 contributes to a global activation of the immune system and thereby improving the survival status of melanoma patients [5–7].